WGU D116 Advanced Pharmacology — OA
& Actual Exam Prep
200 Advanced-Level Practice Questions | Derived from NAPLEX, NCLEX-RN
Advanced, PharmD Board Review & Clinical Pharmacology Sources
1. A patient with heart failure is prescribed carvedilol. Which pharmacodynamic
mechanism explains its dual benefit in this condition?
A) Selective β1-blockade reducing cardiac workload only B) Non-selective β-blockade plus α1-
blockade reducing preload, afterload, and sympathetic stimulation C) ACE inhibition combined
with diuretic effect D) Calcium channel blockade reducing myocardial oxygen demand
(Correct Answer: B) Non-selective β-blockade plus α1-blockade reducing preload,
afterload, and sympathetic stimulation Rationale: Carvedilol is a non-selective β1/β2-blocker
with additional α1-adrenergic blocking properties. This dual mechanism reduces sympathetic
nervous system stimulation of the failing heart (β-blockade) while also reducing systemic
vascular resistance via α1-blockade, decreasing afterload. This combination produces superior
mortality reduction in HFrEF compared to selective β1-blockers.
2. A patient taking warfarin is started on rifampin for tuberculosis. The expected
pharmacokinetic interaction is:
A) Rifampin inhibits CYP2C9, increasing warfarin levels and bleeding risk B) Rifampin induces
CYP2C9, increasing warfarin metabolism and reducing anticoagulant effect C) Rifampin
displaces warfarin from protein binding, causing toxicity D) Rifampin inhibits P-glycoprotein,
increasing warfarin absorption
(Correct Answer: B) Rifampin induces CYP2C9, increasing warfarin metabolism and
reducing anticoagulant effect Rationale: Rifampin is one of the most potent CYP enzyme
inducers known, inducing CYP1A2, CYP2C9, CYP2C19, CYP3A4, and P-glycoprotein.
Warfarin (S-enantiomer) is primarily metabolized by CYP2C9. Rifampin dramatically increases
warfarin clearance, potentially reducing INR to subtherapeutic levels. Warfarin doses may need
to increase 5-fold. The effect persists 2–4 weeks after rifampin discontinuation.
3. Which pharmacokinetic parameter best describes the extent of drug absorption from the
systemic circulation compared to intravenous administration?
,A) Volume of distribution (Vd) B) Half-life (t½) C) Bioavailability (F) D) Clearance (CL)
(Correct Answer: C) Bioavailability (F) Rationale: Bioavailability (F) is the fraction of an
administered dose that reaches systemic circulation unchanged. IV administration has 100%
bioavailability (F=1.0). Oral bioavailability is reduced by first-pass metabolism, incomplete
absorption, and gut wall metabolism. F = (AUC oral × Dose IV) / (AUC IV × Dose oral). This
parameter determines the oral dose needed to achieve equivalent plasma levels to IV
administration.
4. A patient with Stage 3 chronic kidney disease (CrCl 30–59 mL/min) requires
anticoagulation. Which agent requires the MOST significant dose adjustment?
A) Warfarin B) Rivaroxaban C) Dabigatran D) Apixaban
(Correct Answer: C) Dabigatran Rationale: Dabigatran is 80% renally eliminated unchanged
— the highest renal dependence of the DOACs. In severe renal impairment (CrCl <30 mL/min),
dabigatran is contraindicated for most indications. Rivaroxaban and apixaban have lesser degrees
of renal elimination (33% and 27%, respectively). Warfarin is hepatically metabolized and does
not require renal dose adjustment. Dabigatran accumulates most significantly with renal
dysfunction.
5. Which mechanism explains the nephroprotective effect of SGLT2 inhibitors
(empagliflozin) in diabetic nephropathy?
A) Directly blocking angiotensin II receptors in the kidney B) Reducing glomerular
hyperfiltration by decreasing tubuloglomerular feedback via reduced sodium-glucose delivery to
the macula densa C) Inhibiting aldosterone secretion, reducing afferent arteriolar pressure D)
Blocking calcium channels in the afferent arteriole
(Correct Answer: B) Reducing glomerular hyperfiltration by decreasing tubuloglomerular
feedback via reduced sodium-glucose delivery to the macula densa Rationale: SGLT2
inhibitors block glucose and sodium reabsorption in the proximal tubule, increasing sodium
delivery to the macula densa. This activates tubuloglomerular feedback, causing afferent
arteriolar constriction and reducing intraglomerular pressure — directly addressing the
glomerular hyperfiltration that drives diabetic nephropathy progression. This mechanism is
independent of their glucose-lowering effect.
6. A patient is administered a drug with zero-order kinetics. Which statement BEST
describes this pharmacokinetic behavior?
,A) The drug is eliminated at a constant fraction of its concentration per unit time B) A constant
amount of drug is eliminated per unit time regardless of concentration C) Doubling the dose
doubles the half-life proportionally D) Plasma concentration decreases exponentially over time
(Correct Answer: B) A constant amount of drug is eliminated per unit time regardless of
concentration Rationale: Zero-order kinetics (saturation kinetics) occur when elimination
pathways are saturated — a constant AMOUNT (not fraction) of drug is eliminated per unit time.
Examples: phenytoin, ethanol, aspirin (high doses). This means half-life increases with
increasing dose (no true half-life). Small dose changes produce disproportionately large plasma
concentration changes, creating a narrow therapeutic window with high toxicity risk at
saturation.
7. A 68-year-old patient on metoprolol succinate develops symptomatic bradycardia (HR
38 bpm). The MOST appropriate pharmacological reversal agent is:
A) Epinephrine 1mg IV B) Atropine 0.5–1mg IV, may repeat up to 3mg total C) Glucagon 3–
5mg IV bolus D) Calcium gluconate 1g IV
(Correct Answer: C) Glucagon 3–5mg IV bolus Rationale: Glucagon is the antidote for beta-
blocker overdose/toxicity. It activates adenyl cyclase through a receptor independent of beta-
adrenergic receptors, increasing cyclic AMP and producing positive chronotropic and inotropic
effects that bypass the blocked beta receptors. Atropine may be tried first for mild bradycardia
but is often ineffective in significant beta-blocker toxicity. High-dose insulin therapy (HIE) is
also used for severe toxicity.
8. The Michaelis-Menten equation describes enzyme kinetics. When drug concentration is
much LESS than Km (drug concentration << Km), elimination follows:
A) Zero-order kinetics B) First-order kinetics C) Mixed-order kinetics D) Non-linear kinetics
(Correct Answer: B) First-order kinetics Rationale: In the Michaelis-Menten equation: Rate
= (Vmax × C) / (Km + C). When C << Km, the equation simplifies to Rate ≈ (Vmax/Km) × C —
a first-order process where elimination rate is proportional to concentration. When C >> Km, the
equation approaches Rate ≈ Vmax — zero-order kinetics. Phenytoin operates near Km at
therapeutic concentrations, explaining its non-linear kinetics within the therapeutic range.
9. A patient receiving lithium develops polyuria and polydipsia. Which mechanism explains
this adverse effect?
, A) Lithium stimulates ADH (vasopressin) release from the posterior pituitary B) Lithium
antagonizes ADH action at V2 receptors in the collecting duct, causing nephrogenic diabetes
insipidus C) Lithium causes central diabetes insipidus by suppressing hypothalamic function D)
Lithium induces osmotic diuresis through glucose excretion
(Correct Answer: B) Lithium antagonizes ADH action at V2 receptors in the collecting
duct, causing nephrogenic diabetes insipidus Rationale: Lithium interferes with ADH-
mediated water reabsorption in the collecting duct by inhibiting adenylyl cyclase and reducing
aquaporin-2 expression. This causes nephrogenic (not central) DI — the kidney doesn't respond
to ADH despite adequate levels. Treatment includes amiloride (reduces lithium entry into
collecting duct cells) and adequate hydration.
10. Which cytochrome P450 enzyme is responsible for metabolizing the majority of drugs
currently in clinical use?
A) CYP1A2 B) CYP2D6 C) CYP3A4 D) CYP2C9
(Correct Answer: C) CYP3A4 Rationale: CYP3A4 is the most abundant hepatic and intestinal
CYP enzyme, responsible for metabolizing approximately 50% of currently marketed drugs. It is
located in the liver and small intestinal enterocytes (explaining significant first-pass metabolism).
Key substrates include statins, calcium channel blockers, immunosuppressants, HIV protease
inhibitors, and many others. Strong inhibitors (azole antifungals, ritonavir) and inducers
(rifampin, carbamazepine) create clinically significant drug interactions.
11. A patient on warfarin has an INR of 8.5 with no active bleeding. The MOST
appropriate management is:
A) Fresh frozen plasma (FFP) infusion immediately B) Hold warfarin, administer oral vitamin K
2.5–5mg, and recheck INR in 24 hours C) Administer 4-factor PCC (prothrombin complex
concentrate) immediately D) Continue warfarin and recheck INR in 1 week
(Correct Answer: B) Hold warfarin, administer oral vitamin K 2.5–5mg, and recheck INR
in 24 hours Rationale: For supratherapeutic INR (>8.0) without bleeding, the ACC/AHA
recommends holding warfarin and administering oral vitamin K (2.5–5mg). Oral vitamin K
effectively lowers INR within 24 hours. IV vitamin K is reserved for serious bleeding or when
faster correction is needed (but carries anaphylaxis risk). FFP and 4-factor PCC are reserved for
life-threatening bleeding requiring immediate reversal.
12. The "first-pass effect" significantly reduces the oral bioavailability of which of the
following drugs?
& Actual Exam Prep
200 Advanced-Level Practice Questions | Derived from NAPLEX, NCLEX-RN
Advanced, PharmD Board Review & Clinical Pharmacology Sources
1. A patient with heart failure is prescribed carvedilol. Which pharmacodynamic
mechanism explains its dual benefit in this condition?
A) Selective β1-blockade reducing cardiac workload only B) Non-selective β-blockade plus α1-
blockade reducing preload, afterload, and sympathetic stimulation C) ACE inhibition combined
with diuretic effect D) Calcium channel blockade reducing myocardial oxygen demand
(Correct Answer: B) Non-selective β-blockade plus α1-blockade reducing preload,
afterload, and sympathetic stimulation Rationale: Carvedilol is a non-selective β1/β2-blocker
with additional α1-adrenergic blocking properties. This dual mechanism reduces sympathetic
nervous system stimulation of the failing heart (β-blockade) while also reducing systemic
vascular resistance via α1-blockade, decreasing afterload. This combination produces superior
mortality reduction in HFrEF compared to selective β1-blockers.
2. A patient taking warfarin is started on rifampin for tuberculosis. The expected
pharmacokinetic interaction is:
A) Rifampin inhibits CYP2C9, increasing warfarin levels and bleeding risk B) Rifampin induces
CYP2C9, increasing warfarin metabolism and reducing anticoagulant effect C) Rifampin
displaces warfarin from protein binding, causing toxicity D) Rifampin inhibits P-glycoprotein,
increasing warfarin absorption
(Correct Answer: B) Rifampin induces CYP2C9, increasing warfarin metabolism and
reducing anticoagulant effect Rationale: Rifampin is one of the most potent CYP enzyme
inducers known, inducing CYP1A2, CYP2C9, CYP2C19, CYP3A4, and P-glycoprotein.
Warfarin (S-enantiomer) is primarily metabolized by CYP2C9. Rifampin dramatically increases
warfarin clearance, potentially reducing INR to subtherapeutic levels. Warfarin doses may need
to increase 5-fold. The effect persists 2–4 weeks after rifampin discontinuation.
3. Which pharmacokinetic parameter best describes the extent of drug absorption from the
systemic circulation compared to intravenous administration?
,A) Volume of distribution (Vd) B) Half-life (t½) C) Bioavailability (F) D) Clearance (CL)
(Correct Answer: C) Bioavailability (F) Rationale: Bioavailability (F) is the fraction of an
administered dose that reaches systemic circulation unchanged. IV administration has 100%
bioavailability (F=1.0). Oral bioavailability is reduced by first-pass metabolism, incomplete
absorption, and gut wall metabolism. F = (AUC oral × Dose IV) / (AUC IV × Dose oral). This
parameter determines the oral dose needed to achieve equivalent plasma levels to IV
administration.
4. A patient with Stage 3 chronic kidney disease (CrCl 30–59 mL/min) requires
anticoagulation. Which agent requires the MOST significant dose adjustment?
A) Warfarin B) Rivaroxaban C) Dabigatran D) Apixaban
(Correct Answer: C) Dabigatran Rationale: Dabigatran is 80% renally eliminated unchanged
— the highest renal dependence of the DOACs. In severe renal impairment (CrCl <30 mL/min),
dabigatran is contraindicated for most indications. Rivaroxaban and apixaban have lesser degrees
of renal elimination (33% and 27%, respectively). Warfarin is hepatically metabolized and does
not require renal dose adjustment. Dabigatran accumulates most significantly with renal
dysfunction.
5. Which mechanism explains the nephroprotective effect of SGLT2 inhibitors
(empagliflozin) in diabetic nephropathy?
A) Directly blocking angiotensin II receptors in the kidney B) Reducing glomerular
hyperfiltration by decreasing tubuloglomerular feedback via reduced sodium-glucose delivery to
the macula densa C) Inhibiting aldosterone secretion, reducing afferent arteriolar pressure D)
Blocking calcium channels in the afferent arteriole
(Correct Answer: B) Reducing glomerular hyperfiltration by decreasing tubuloglomerular
feedback via reduced sodium-glucose delivery to the macula densa Rationale: SGLT2
inhibitors block glucose and sodium reabsorption in the proximal tubule, increasing sodium
delivery to the macula densa. This activates tubuloglomerular feedback, causing afferent
arteriolar constriction and reducing intraglomerular pressure — directly addressing the
glomerular hyperfiltration that drives diabetic nephropathy progression. This mechanism is
independent of their glucose-lowering effect.
6. A patient is administered a drug with zero-order kinetics. Which statement BEST
describes this pharmacokinetic behavior?
,A) The drug is eliminated at a constant fraction of its concentration per unit time B) A constant
amount of drug is eliminated per unit time regardless of concentration C) Doubling the dose
doubles the half-life proportionally D) Plasma concentration decreases exponentially over time
(Correct Answer: B) A constant amount of drug is eliminated per unit time regardless of
concentration Rationale: Zero-order kinetics (saturation kinetics) occur when elimination
pathways are saturated — a constant AMOUNT (not fraction) of drug is eliminated per unit time.
Examples: phenytoin, ethanol, aspirin (high doses). This means half-life increases with
increasing dose (no true half-life). Small dose changes produce disproportionately large plasma
concentration changes, creating a narrow therapeutic window with high toxicity risk at
saturation.
7. A 68-year-old patient on metoprolol succinate develops symptomatic bradycardia (HR
38 bpm). The MOST appropriate pharmacological reversal agent is:
A) Epinephrine 1mg IV B) Atropine 0.5–1mg IV, may repeat up to 3mg total C) Glucagon 3–
5mg IV bolus D) Calcium gluconate 1g IV
(Correct Answer: C) Glucagon 3–5mg IV bolus Rationale: Glucagon is the antidote for beta-
blocker overdose/toxicity. It activates adenyl cyclase through a receptor independent of beta-
adrenergic receptors, increasing cyclic AMP and producing positive chronotropic and inotropic
effects that bypass the blocked beta receptors. Atropine may be tried first for mild bradycardia
but is often ineffective in significant beta-blocker toxicity. High-dose insulin therapy (HIE) is
also used for severe toxicity.
8. The Michaelis-Menten equation describes enzyme kinetics. When drug concentration is
much LESS than Km (drug concentration << Km), elimination follows:
A) Zero-order kinetics B) First-order kinetics C) Mixed-order kinetics D) Non-linear kinetics
(Correct Answer: B) First-order kinetics Rationale: In the Michaelis-Menten equation: Rate
= (Vmax × C) / (Km + C). When C << Km, the equation simplifies to Rate ≈ (Vmax/Km) × C —
a first-order process where elimination rate is proportional to concentration. When C >> Km, the
equation approaches Rate ≈ Vmax — zero-order kinetics. Phenytoin operates near Km at
therapeutic concentrations, explaining its non-linear kinetics within the therapeutic range.
9. A patient receiving lithium develops polyuria and polydipsia. Which mechanism explains
this adverse effect?
, A) Lithium stimulates ADH (vasopressin) release from the posterior pituitary B) Lithium
antagonizes ADH action at V2 receptors in the collecting duct, causing nephrogenic diabetes
insipidus C) Lithium causes central diabetes insipidus by suppressing hypothalamic function D)
Lithium induces osmotic diuresis through glucose excretion
(Correct Answer: B) Lithium antagonizes ADH action at V2 receptors in the collecting
duct, causing nephrogenic diabetes insipidus Rationale: Lithium interferes with ADH-
mediated water reabsorption in the collecting duct by inhibiting adenylyl cyclase and reducing
aquaporin-2 expression. This causes nephrogenic (not central) DI — the kidney doesn't respond
to ADH despite adequate levels. Treatment includes amiloride (reduces lithium entry into
collecting duct cells) and adequate hydration.
10. Which cytochrome P450 enzyme is responsible for metabolizing the majority of drugs
currently in clinical use?
A) CYP1A2 B) CYP2D6 C) CYP3A4 D) CYP2C9
(Correct Answer: C) CYP3A4 Rationale: CYP3A4 is the most abundant hepatic and intestinal
CYP enzyme, responsible for metabolizing approximately 50% of currently marketed drugs. It is
located in the liver and small intestinal enterocytes (explaining significant first-pass metabolism).
Key substrates include statins, calcium channel blockers, immunosuppressants, HIV protease
inhibitors, and many others. Strong inhibitors (azole antifungals, ritonavir) and inducers
(rifampin, carbamazepine) create clinically significant drug interactions.
11. A patient on warfarin has an INR of 8.5 with no active bleeding. The MOST
appropriate management is:
A) Fresh frozen plasma (FFP) infusion immediately B) Hold warfarin, administer oral vitamin K
2.5–5mg, and recheck INR in 24 hours C) Administer 4-factor PCC (prothrombin complex
concentrate) immediately D) Continue warfarin and recheck INR in 1 week
(Correct Answer: B) Hold warfarin, administer oral vitamin K 2.5–5mg, and recheck INR
in 24 hours Rationale: For supratherapeutic INR (>8.0) without bleeding, the ACC/AHA
recommends holding warfarin and administering oral vitamin K (2.5–5mg). Oral vitamin K
effectively lowers INR within 24 hours. IV vitamin K is reserved for serious bleeding or when
faster correction is needed (but carries anaphylaxis risk). FFP and 4-factor PCC are reserved for
life-threatening bleeding requiring immediate reversal.
12. The "first-pass effect" significantly reduces the oral bioavailability of which of the
following drugs?
